FDA Reviews Compounding Pharmacies for Peptide Manufacturing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HIMS?
Source: seekingalpha
- Peptide Drug Review: The FDA convened an independent advisory group to discuss allowing compounding pharmacies to manufacture specific peptides, which were removed from the list of drugs permitted for compounding in 2023, indicating a potential shift in regulatory policy that could impact market supply.
- Meeting Schedule: The upcoming meetings will focus on seven peptides scheduled for July 23 and 24, while another five will be reviewed at a future meeting before the end of February 2027, highlighting the FDA's ongoing scrutiny of peptide drugs.
- Growing Market Demand: Peptides are gaining attention for their vital roles in biological functions such as collagen formation and inflammation, particularly due to promotion by online influencers, despite limited data on their effectiveness and safety, which may create market opportunities for related companies.
- Policy Advocacy: Health Secretary Robert F. Kennedy Jr. stated in a podcast that he is advocating for the FDA to reverse restrictions on peptides, emphasizing his personal positive experiences with their use, which could influence public acceptance and demand for peptide products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 21.360
Low
16.50
Averages
32.95
High
60.00
Current: 21.360
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Reviews Compounding Pharmacies for Peptide Manufacturing
- Peptide Drug Review: The FDA convened an independent advisory group to discuss allowing compounding pharmacies to manufacture specific peptides, which were removed from the list of drugs permitted for compounding in 2023, indicating a potential shift in regulatory policy that could impact market supply.
- Meeting Schedule: The upcoming meetings will focus on seven peptides scheduled for July 23 and 24, while another five will be reviewed at a future meeting before the end of February 2027, highlighting the FDA's ongoing scrutiny of peptide drugs.
- Growing Market Demand: Peptides are gaining attention for their vital roles in biological functions such as collagen formation and inflammation, particularly due to promotion by online influencers, despite limited data on their effectiveness and safety, which may create market opportunities for related companies.
- Policy Advocacy: Health Secretary Robert F. Kennedy Jr. stated in a podcast that he is advocating for the FDA to reverse restrictions on peptides, emphasizing his personal positive experiences with their use, which could influence public acceptance and demand for peptide products.
See More
Hims & Hers Ventures into AI Health Tools
- AI Tool Development: Hims & Hers is developing AI tools aimed at enhancing user health, with launches expected later this year, showcasing the company's innovative potential in the healthcare sector.
- Market Disruption Potential: If successfully implemented, AI could serve as a disruptive force in healthcare, positioning Hims & Hers as a long-term winner in the market and enhancing its competitive edge.
- Management Vision: The company's management recently outlined their vision for AI, emphasizing various potential use cases, indicating a proactive stance towards future developments.
- Investor Expectations: With upcoming product launches, investors should monitor Hims & Hers' progress in the AI space, which could positively impact its stock price.
See More
Hims & Hers Faces Legal Investigation and Lawsuit
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Hims & Hers Health, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could undermine investor confidence.
- FDA Statement Impact: The FDA has indicated it will take decisive steps to restrict the use of GLP-1 active pharmaceutical ingredients, which could significantly negatively impact Hims & Hers' market sales, particularly in the non-FDA-approved compounded drug sector.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, which adds to the company's legal risks and could adversely affect its financial performance.
- Significant Stock Price Drop: On February 9, 2026, shares of Hims & Hers fell by more than 17.8% during trading, reflecting market concerns about the company's future prospects and a decline in investor confidence.
See More
HIMS & HERS: BOFA Global Research Lowers Price Target to $21.00 from $23.00
- Price Reduction Announcement: HIMS & HERS has announced a price cut for its services, reducing the cost from $23.00 to $21.00.
- Impact on Consumers: This price adjustment aims to make healthcare services more accessible to consumers, potentially increasing customer engagement and satisfaction.
See More
Hims Partners with Novo Nordisk for Wegovy Rollout
- Prescription Target Increase: CEO Andrew Dudum announced that Hims & Hers Health Inc. is on track to deliver over 100,000 Wegovy prescriptions monthly, marking a strategic shift in its weight-loss business that is expected to attract more customers and enhance market share.
- Diverse Medication Options: Under the agreement with Novo Nordisk, Hims will offer multiple Wegovy injection doses (ranging from 0.25 mg to 2.4 mg) and oral formulations, catering to various patient needs, thereby enhancing customer loyalty and satisfaction.
- Increased Shareholder Confidence: CFO Yemi Okupe disclosed plans to sell approximately 240,560 shares worth about $4.89 million under a Rule 10b5-1 trading plan, indicating management's confidence in future growth and reflecting a positive outlook on market opportunities.
- Rising Market Optimism: Despite a nearly 30% decline in HIMS stock over the past year, Barclays raised its price target to $29, believing that the partnership with Novo Nordisk eliminates legal uncertainties and signals expanding opportunities tied to new product launches.
See More
New Derivative Income ETFs Pose Unnecessary Risks
High Yield ETF: An exchange-traded fund (ETF) linked to Hims & Hers Health offers an enticing 80% yield.
Investment Temptation: The potential for high returns may attract investors despite the underlying product's association with erectile dysfunction.
See More
FDA Reviews Compounding Pharmacies for Peptide Manufacturing
- Peptide Drug Review: The FDA convened an independent advisory group to discuss allowing compounding pharmacies to manufacture specific peptides, which were removed from the list of drugs permitted for compounding in 2023, indicating a potential shift in regulatory policy that could impact market supply.
- Meeting Schedule: The upcoming meetings will focus on seven peptides scheduled for July 23 and 24, while another five will be reviewed at a future meeting before the end of February 2027, highlighting the FDA's ongoing scrutiny of peptide drugs.
- Growing Market Demand: Peptides are gaining attention for their vital roles in biological functions such as collagen formation and inflammation, particularly due to promotion by online influencers, despite limited data on their effectiveness and safety, which may create market opportunities for related companies.
- Policy Advocacy: Health Secretary Robert F. Kennedy Jr. stated in a podcast that he is advocating for the FDA to reverse restrictions on peptides, emphasizing his personal positive experiences with their use, which could influence public acceptance and demand for peptide products.
See More
Hims & Hers Ventures into AI Health Tools
- AI Tool Development: Hims & Hers is developing AI tools aimed at enhancing user health, with launches expected later this year, showcasing the company's innovative potential in the healthcare sector.
- Market Disruption Potential: If successfully implemented, AI could serve as a disruptive force in healthcare, positioning Hims & Hers as a long-term winner in the market and enhancing its competitive edge.
- Management Vision: The company's management recently outlined their vision for AI, emphasizing various potential use cases, indicating a proactive stance towards future developments.
- Investor Expectations: With upcoming product launches, investors should monitor Hims & Hers' progress in the AI space, which could positively impact its stock price.
See More
Hims & Hers Faces Legal Investigation and Lawsuit
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Hims & Hers Health, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could undermine investor confidence.
- FDA Statement Impact: The FDA has indicated it will take decisive steps to restrict the use of GLP-1 active pharmaceutical ingredients, which could significantly negatively impact Hims & Hers' market sales, particularly in the non-FDA-approved compounded drug sector.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, which adds to the company's legal risks and could adversely affect its financial performance.
- Significant Stock Price Drop: On February 9, 2026, shares of Hims & Hers fell by more than 17.8% during trading, reflecting market concerns about the company's future prospects and a decline in investor confidence.
See More
HIMS & HERS: BOFA Global Research Lowers Price Target to $21.00 from $23.00
- Price Reduction Announcement: HIMS & HERS has announced a price cut for its services, reducing the cost from $23.00 to $21.00.
- Impact on Consumers: This price adjustment aims to make healthcare services more accessible to consumers, potentially increasing customer engagement and satisfaction.
See More
Hims Partners with Novo Nordisk for Wegovy Rollout
- Prescription Target Increase: CEO Andrew Dudum announced that Hims & Hers Health Inc. is on track to deliver over 100,000 Wegovy prescriptions monthly, marking a strategic shift in its weight-loss business that is expected to attract more customers and enhance market share.
- Diverse Medication Options: Under the agreement with Novo Nordisk, Hims will offer multiple Wegovy injection doses (ranging from 0.25 mg to 2.4 mg) and oral formulations, catering to various patient needs, thereby enhancing customer loyalty and satisfaction.
- Increased Shareholder Confidence: CFO Yemi Okupe disclosed plans to sell approximately 240,560 shares worth about $4.89 million under a Rule 10b5-1 trading plan, indicating management's confidence in future growth and reflecting a positive outlook on market opportunities.
- Rising Market Optimism: Despite a nearly 30% decline in HIMS stock over the past year, Barclays raised its price target to $29, believing that the partnership with Novo Nordisk eliminates legal uncertainties and signals expanding opportunities tied to new product launches.
See More
New Derivative Income ETFs Pose Unnecessary Risks
High Yield ETF: An exchange-traded fund (ETF) linked to Hims & Hers Health offers an enticing 80% yield.
Investment Temptation: The potential for high returns may attract investors despite the underlying product's association with erectile dysfunction.
See More
